Compare ACCS & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACCS | INMB |
|---|---|---|
| Founded | 1988 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Publishing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.0M | 40.1M |
| IPO Year | N/A | 2019 |
| Metric | ACCS | INMB |
|---|---|---|
| Price | $7.08 | $1.44 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 3 |
| Target Price | ★ $14.00 | $4.30 |
| AVG Volume (30 Days) | 19.6K | ★ 332.6K |
| Earning Date | 03-24-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $22,646,000.00 | $50,000.00 |
| Revenue This Year | $0.18 | $264.29 |
| Revenue Next Year | $7.16 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 42.30 | 19.05 |
| 52 Week Low | $6.86 | $1.38 |
| 52 Week High | $13.35 | $11.64 |
| Indicator | ACCS | INMB |
|---|---|---|
| Relative Strength Index (RSI) | 25.85 | 41.81 |
| Support Level | $6.86 | $1.44 |
| Resistance Level | $7.61 | $1.67 |
| Average True Range (ATR) | 0.37 | 0.12 |
| MACD | -0.20 | -0.01 |
| Stochastic Oscillator | 6.84 | 12.82 |
ACCESS Newswire Inc is a Public Relations (PR) and Investor Relations (IR) solutions provider. The group focuses on innovation, customer service, and value-driven offerings, ACCESS Newswire empowers brands.
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.